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Abstract
Background: Despite the extensive genetic diversity of HIV-1, viral evolution in response to immune selective pressures follows
broadly predictable mutational patterns. Sites and pathways of Human Leukocyte-Antigen (HLA)-associated polymorphisms in
HIV-1 have been identified through the analysis of population-level data, but the full extent of immune escape pathways
remains incompletely characterized. Here, in the largest analysis of HIV-1 subtype B sequences undertaken to date, we identify
HLA-associated polymorphisms in the three HIV-1 proteins most commonly considered in cellular-based vaccine strategies.
Results are organized into protein-wide escape maps illustrating the sites and pathways of HLA-driven viral evolution.
Methodology/Principal Findings: HLA-associated polymorphisms were identified in HIV-1 Gag, Pol and Nef in a multicenter
cohort of .1500 chronically subtype-B infected, treatment-naı¨ve individuals from established cohorts in Canada, the USA
and Western Australia. At q#0.05, 282 codons commonly mutating under HLA-associated immune pressures were identified
in these three proteins. The greatest density of associations was observed in Nef (where close to 40% of codons exhibited a
significant HLA association), followed by Gag then Pol (where ,15–20% of codons exhibited HLA associations), confirming
the extensive impact of immune selection on HIV evolution and diversity. Analysis of HIV codon covariation patterns
identified over 2000 codon-codon interactions at q#0.05, illustrating the dense and complex networks of linked escape and
secondary/compensatory mutations.
Conclusions/Significance: The immune escape maps and associated data are intended to serve as a user-friendly guide to the
locations of common escape mutations and covarying codons in HIV-1 subtype B, and as a resource facilitating the systematic
identification and classification of immune escape mutations. These resources should facilitate research in HIV epitope
discovery and host-pathogen co-evolution, and are relevant to the continued search for an effective CTL-based AIDS vaccine.
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Introduction
Cytotoxic T-Lymphocytes (CTL) eliminate virus-infected cells by
recognizing virus-derived peptides (‘‘epitopes’’) presented by Human
Leukocyte Antigen (HLA) class I molecules on the infected cell surface.
The HLA-restricted CTL response is believed to play a major role in
the immune control of HIV-1 infection [1,2,3,4,5,6], and it is
generally believed that an effective AIDS vaccine will have to elicit
cellular as well as humoral (antibody) responses [7,8,9,10,11]. The
genes encoding HLA class I are among the most polymorphic in the
human genome [12]: each individual expresses up to six different class
I alleles (two at each of the A, B and C loci) out of a pool of over two
thousand allelic variants defined to date. Each unique HLA molecule
is capable of presenting a broad but finite array of epitopes, defined by
HLA allele-specific binding motifs. This extensive genetic diversity
serves as a mechanism whereby the human immune system, on both
the individual as well as on a population basis, is equipped to recognize
a vast array of epitopes from a broad range of pathogens. In addition,
this extensive diversity means that, at both the individual as well as the
population level, the human immune response exerts a complex array
of evolutionary selective pressures driving viral evolution [13,14] in
equally intricate, sometimes even conflicting [15,16] ways.
One of the major mechanisms whereby HIV evades the cellular
immune response is through the selection of HLA-restricted CTL
escape mutations that allow the virus to evade immune recognition
[17,18,19,20]. Escape mutations may interfere with intracellular
epitope processing [21,22], disrupt peptide-HLA binding [23,24],
or disrupt recognition of the peptide/HLA complex by the T-cell
receptor [25,26].
Despite the extensive genetic diversity of both HIV-1 and HLA,
recent studies indicate that viral evolution in response to immune
selective pressures follows generally predictable patterns and kinetics
[13,14,15,27,28,29,30]. For example, in B*57-expressing individu-
als, the B*57-associated T242N escape mutation in Gag is selected
mere weeks after infection [31,32,33], whereas the B*27-associated
R264K (Gag) may take years to develop despite strong continuous
immune pressure in individuals expressing B*27 [24,34]. Further-
more, both T242N and R264K are typically accompanied by a
well-defined set of compensatory mutations [24,35,36]. The
development of improved statistical methods [37] combined with
the availability of large cohorts for which HIV sequences and HLA
data are available has facilitated the systematic identification of
HLA-associated CTL escape mutations, both within [15,28,29,38]
and across [27] HIV subtypes. Due to the extensive diversity of both
HLA and HIV, the identification of mutational escape patterns
requires large, well-powered datasets; thus, additional data are
needed in order to refine existing escape maps. Indeed, just as the
systematic identification of antiretroviral resistance mutations [39]
has been of paramount importance to the design and monitoring of
HIV therapies [40], the comprehensive elucidation of immune
escape pathways will be of relevance to HIV vaccine research.
Here, we identify HLA-associated polymorphisms within the
three HIV-1 proteins most commonly considered in cellular-based
vaccine design strategies (Gag, Pol and Nef) in a combined analysis
of three established cohorts totaling .1500 HIV-infected,
antiretroviral-naı¨ve individuals. We organize results into protein-
wide escape maps illustrating the sites and pathways of immune-
driven viral evolution, and hope that these maps will serve as
useful reference material for researchers interested in CTL epitope
discovery, host-pathogen co-evolution, and HIV vaccine design.
Materials and Methods
Analysis of three established cohorts and formation of
the International HIV Adaptation Collaborative (IHAC)
We merged HLA class I and HIV-1 Gag, Pol and Nef sequence
data from three existing cohorts of chronically-HIV-infected,
antiretroviral naı¨ve individuals previously featured in population-
level investigations of HIV immune escape: the British Columbia
HOMER cohort (British Columbia, Canada, N = 765) [15,38], the
Western Australian HIV Cohort Study (WAHCS; Western
Australia, Australia N = 230) [14,37], and US AIDS Clinical
Trials Group (ACTG) protocols 5142 participants [41] who also
provided human DNA under ACTG protocol 5128 [42]
(N = 555). We have assigned the name ‘‘International HIV
Adaptation Collaborative’’ (IHAC) to describe this multicenter,
international cohort.
Ethics Statement
Ethical Approval was obtained through the following Institu-
tional Review Boards: Providence Health Care/University of
British Columbia; Royal Perth Hospital Ethics Committee; and
the NIH’s National Institute of Allergy and Infectious Diseases
(NIAID) Clinical Science Review Committee (CSRC).
Genotyping methods and inter-laboratory methods
comparison for quality control
HIV and HLA data collection for HOMER cohort participants
was performed at the BC Centre for Excellence in HIV/AIDS,
Vancouver, Canada. Here, HIV RNA was extracted from plasma
using standard methods and regions of interest amplified by nested
RT-PCR using HIV-specific primers. PCR amplicons were bulk
sequenced on an Applied Biosystems 3100, 3700 and/or 3730
automated DNA sequencer. Data were analyzed using ‘Se-
quencher’ (Genecodes) or custom software RE_Call. Nucleotide
mixtures were called if the height of the secondary peak exceeded
25% of the height of the dominant peak. HLA class I typing was
performed using an in-house sequence-based typing protocol and
interpretation algorithm [15].
HIV and HLA data collection for the WAHCS and ACTG
5142/5128 cohort participants was performed at the Centre for
Clinical Immunology and Biological Statistics (CCIBS) laboratory
in Perth, Australia. Plasma HIV RNA was extracted using
standard methods and nearly complete viral genomes amplified
using nested RT-PCR. PCR amplicons were bulk-sequenced using
Applied Biosystems 3730 automated sequencing. Data were
analyzed using semi-automated ASSIGN software with a nucle-
otide mixture threshold of 15% after consideration of the signal/
noise ratio, yielding near-full genome sequences. High-resolution
HLA class I typing was performed using sequence-based methods
and allele interpretation was performed using ASSIGN [41].
To rule out potential biases due to differences in sequence
analysis strategies between study sites, an inter-laboratory DNA
sequencing comparison between the Vancouver and Perth
laboratories was performed prior to merging data. A total of
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42599 base pairs of sequence data covering Gag, Pol and Nef were
exchanged and analyzed using site-specific software and proce-
dures in a blinded fashion. Overall inter-laboratory concordance
was 42429 out of 42599 calls, or 99.6%. Of the 170 discordant
calls, 169 (99.4%) were due to the presence of a nucleotide mixture
called by one laboratory but not the other, with a tendency of the
Vancouver lab to call more mixtures than the Perth lab.
After verification of inter-laboratory concordance, Gag, Pol and
Nef sequences were extracted from the nearly-full genome WAHCS/
ACTG sequences using GeneCutter (http://www.hiv.lanl.gov/
content/sequence/GENE_CUTTER/cutter.html) before merging
with the BC HOMER sequence data. The merged sequence datasets
were aligned to HIV-1 subtype B reference strain HXB2 (GenBank
Accession No. K03455) using a modified NAP algorithm [40]. HLA
class I types were summarized to two-digit resolution. Final HLA/
HIV sequence datasets comprised N = 1294, 1383 and 1299 for Gag,
Pol and Nef, respectively. Sequence subtypes verified by comparison
to subtype references in the Los Alamos HIV Database (http://www.
hiv.lanl.gov); .95% of sequences in this study were subtype B.
GenBank Accession Numbers
Gag, protease/RT (codons 1–400 only) and nef sequences from
the HOMER cohort were previously deposited in GenBank
[15,38]. Accession numbers of additional HOMER protease/RT
(codon 1–400 only) sequences included in the present study are
GQ303719-GQ303727; full-length protease/RT sequences are
GQ303728-GQ303867 and HOMER RT codon 401–560
sequences are GQ303868-GQ304249. HOMER integrase se-
quences are FJ812899-FJ813480. Linked HLA/HIV datasets from
the BC HOMER cohort are available for sharing with individual
researchers following application to, and approval by the UBC/
Providence Health Care Research Ethics Board; please contact the
corresponding author for more information. GenBank Accession
Numbers for ACTG 5142/5128 cohort sequences are GQ371216-
GQ371763 (Gag), GQ371764-GQ372317 (Pol) and GQ372318-
GQ372824 plus GQ398382-GQ398387 (Nef). GenBank Acces-
sion numbers for the full/partial HIV genome sequences from
WAHCS, from which Gag, Pol and Nef were extracted and used
here, are AY856956-AY857186.
Identification of HLA-associated polymorphisms:
Overview
The identification of HLA-associated polymorphisms in popu-
lation-based datasets is complicated by three potential confound-
ing factors: HIV phylogeny, HIV codon covariation, and Linkage
Disequilibrium between HLA alleles [27]. HIV phylogeny acts as
a confounder because HIV sequences are related to one another
through descent from a common ancestor, with sequences
displaying greater or lesser similarity to one another depending
on the length of time since divergence. Thus, statistical tests that
assume independent and identically distributed (iid) observations,
such as chi-squared or Fisher’s exact tests, may lead to inflated
false-negative and false-positive rates if applied directly [27,37].
Similarly, Linkage Disequilibrium (LD) between HLA alleles also
exerts confounding effects. If LD is not addressed, linked HLA
alleles may appear associated with the same mutational patterns,
when in reality, escape is driven by one allele only
[14,15,27,28,29]. For this reason, analytical methods have been
developed to account for both HIV phylogeny and HLA LD [27].
HIV codon covariation acts as an additional, albeit more subtle,
confounder [27]. Although the phylogenetic tree adjusts for the
underlying evolutionary relationships between HIV sequences,
immune selection pressures may lead to reproducible patterns of
mutations at linked sites, even in sequences located far apart in the
tree. An example of this may be an escape pattern where a
primary mutation is first selected in context of a specific HLA
allele, followed by a compensatory mutation at a secondary site
[24,35,36]. If codon covariation is not accounted for, both the
primary and secondary sites may be identified as being associated
with the HLA allele in question. Technically, this result would not
be incorrect (as both primary and secondary mutations are
selected by the HLA allele). However, if the goal is to discriminate
between HLA-associated polymorphisms selected directly (for
example, mutations that compromise epitope processing, peptide-
HLA binding and/or T-cell recognition), from those that are
selected indirectly (such as compensatory or secondary mutations),
correction for codon covariation is necessary. A method that
simultaneously accounts for HIV phylogeny and codon covaria-
tion, in addition to HLA linkage disequilibrium, has recently been
developed by Carlson et al [27], and we have applied it in this
study.
Identification of HLA-associated polymorphisms:
statistical methods
A detailed description of the HIV Phylogeny, HLA LD and
HIV codon-covariation-corrected method is published in [27].
Briefly, a maximum likelihood phylogenetic tree is constructed for
each gene and a model of conditional adaptation is inferred for
each observed amino acid at each codon. In this model, the amino
acid is assumed to evolve independently down the phylogeny, until
it reaches the observed hosts. In each host, the selection pressure
arising from HLA-mediated T-cell responses and amino acid
covariation is directly modeled using a stochastic additive process.
To identify which factors contribute to the selection pressure, a
forward selection procedure is employed, in which the most
significant association is iteratively added to the model, with p-
values computed using the likelihood ratio test. To increase our
statistical power, each codon is divided into a set of binary
variables, one for each observed amino acid. In addition, we only
consider pairs of variables for which the observed or expected
value for each value of the contingency table is at least three.
Definition of Statistical Significance
Statistical significance is reported using q-values, the p-value
analogue of the false discovery rate (FDR) for each p-value
threshold [43]. The FDR is the expected proportion of false
positives among results deemed significant at a given threshold.
For example, at a q#0.2, we expect a false-positive proportion of
20% among identified associations. The q-value threshold used for
constructing the immune escape maps was q#0.05, meaning that
we would expect only a 5% false-positive proportion among
associations displayed on our maps. Tables S1 and S2 list all HLA-
and covariation associations, respectively, with q#0.2 (see
supporting information).
Classification and Nomenclature of HLA-associated
polymorphisms
Using this method, HLA-associated polymorphisms are
grouped into two categories: (1) amino acids significantly enriched
in the presence of the HLA allele in question (and vice versa), and
(2) amino acids significantly depleted in the presence of the HLA
allele in question (and vice versa). We refer to these two categories
as the ‘‘adapted’’ and ‘‘nonadapted’’ forms, respectively. Previous
studies, including some by our group, have employed various
nomenclature systems for these polymorphisms: the ‘‘adapted’’
forms may also be referred to as ‘‘escape mutants’’ or ‘‘resistant
forms’’, while the ‘‘nonadapted’’ forms have been referred to as
HIV-1 Immune Escape Maps
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‘‘susceptible’’, ‘‘wild-type’’ and/or ‘‘reversion’’ forms. We will
endeavour to use the ‘‘adapted/nonadapted’’ nomenclature in all
future studies of this type.
HIV covariation-corrected analysis: a point to consider
HIV proteins often contain multiple epitopes restricted by the
same HLA allele (B*57 TW10 and IW9 in Gag, for example). On
occasion, we have observed that the covariation-corrected analysis
identifies mutations in epitopes restricted by the same HLA allele
as being ‘‘linked’’, when in fact a more likely explanation is that
that they arise due to HLA-restricted targeting and escape within
multiple epitopes, either simultaneously or sequentially over the
disease course [27,32,44,45,46,47]. In order to not exclude any
potentially important escape mutations from our figures, we ran
the analysis with and without the covariation correction, and
included all HLA-associated polymorphisms identified by either
method in the escape maps. In the escape maps, the covariation-
corrected and uncorrected associations are differentiated by the
use of uppercase and lowercase letters, respectively.
Results
HLA-associated polymorphisms were identified in HIV-1 Gag,
Pol and Nef in a multicenter cohort of.1500 chronically-infected,
treatment-naı¨ve individuals using published methods featuring a
correction for HIV phylogeny, HLA linkage disequilibrium and
HIV codon covariation [27]. The false discovery rate [43] was
used to account for multiple tests.
At the conservative threshold of q#0.05, 282 HIV codons
commonly mutating under HLA-associated immune pressure in
Gag, Pol and Nef were identified. These polymorphisms were
observed at 74 (of 206; 36%) Nef codons, 80 (of 500; 16%) Gag
codons, and 128 (of 947; 14%) codons in Pol. At a more liberal
threshold of q#0.2, the total number of observed codons
harboring HLA-associated polymorphisms increased to 442,
which included 113 (55%), 130 (26%), 199 (21%) of codons in
Nef, Gag and Pol, respectively. These data confirm the results of
previous population-based studies reporting greater density of
HLA-associated polymorphisms in Nef than in Gag or Pol
[15,29,41,48]. Moreover results underscore the observation that
the effects of HLA-associated selection pressures on HIV-1
evolution are extensive and predictable.
All HLA-associated polymorphisms at q#0.05 were organized
into gene-wide ‘‘immune escape maps’’ (Figures 1, 2, 3, 4, 5)
indicating their location, HLA restriction, specific amino acids,
and their direction of association (‘‘adapted’’ vs. ‘‘non-adapted’’)
with respect to the current HIV subtype B consensus sequence
(http://www.hiv.lanl.gov). Published, optimally-described CTL
epitopes [49] containing HLA-associated polymorphisms are also
shown. In addition, the maps discriminate between HLA-
associated polymorphisms directly attributable to selection pres-
sure by the allele (meaning that they survive correction for HIV
covariation), from those that may be better explained indirectly
(meaning that their occurrence may be better explained by the
presence of an HLA-associated covarying residue, rather than the
allele itself). The full list of direct (covariation-corrected) plus
indirect (covariation uncorrected) HLA-associated polymorphisms
within each viral protein at q#0.2 is provided in Table S1.
As described in the methods, we also undertook an HIV
codon-covariation analysis that, besides identifying direct HLA-
associated polymorphisms, also identified all pairwise amino
acid-amino acid (aa-aa) associations within a given HIV protein
[27]. The HIV codon covariation analysis can be used to identify
linked pathways of immune escape, as well as putative secondary
and/or compensatory mutations associated with a primary
escape site. The codon covariation analysis identified .7000
intra-protein aa-aa correlations occurring at .4500 codon pairs,
illustrating the dense and complex networks of covarying amino
acids in HIV (Table S2). Indeed, if one sums up the total number
of codons harboring HLA-associated polymorphisms, plus the
co-varying sites immediately associated with them, the total
proportion of codons in Nef that are either directly or indirectly
associated with HLA selection pressures reaches 77%. For Gag
and Pol, the corresponding proportions are 55% and 44%,
respectively.
The sheer density of the intraprotein codon covariation network
renders the task of displaying these data rather challenging, but
Carlson et al have developed an elegant tool for data visualization
that is freely available [27]. Here, the amino acid sequence of a
protein is displayed in a counterclockwise circle starting at the 3
o’clock position (Figures 6 and 7). Any HLA alleles associated with
variation at those sites are indicated at the corresponding positions
outside the circle, while covarying amino acids are joined together
by arcs within the circle. The strength of the association (q-value) is
indicated by the color of the arc.
HLA-associated intraprotein codon networks in Gag for HLA-
B*57 and HLA-B*27 are shown in Figures 6 and 7, respectively.
These two alleles were chosen as examples due to their association
with slower HIV disease progression in numerous epidemiologic
studies [5,34,50]. Similarly, Gag was chosen in light of
accumulating evidence that Gag-specific CD8 T-cell responses
may contribute substantially to HIV immune containment
[51,52,53] as well as the observation that B*57 and B*27-
associated escape mutations in Gag are associated with measurable
costs to viral replication capacity [35,36,54], which may be
partially rescued by compensatory mutations at secondary sites
[35,36]. All direct (covariation-corrected) and indirect (covariation
uncorrected) B*57-associated Gag polymorphisms at q#0.2 are
identified at their respective positions along the circle’s circumfer-
ence: For B*57 (figure 6), this corresponds to codons 146, 147,
163, 173, 242, 248, 315, 340, 435 and 449. Within the circle, all
q#0.2 ‘‘one-hop’’ associations with these codons (meaning, Gag
codons identified as covarying with them) are connected via arcs.
For example, if the B*57-associated polymorphism at Gag position
242 is considered the ‘‘predictor variable’’ (see Table S2), then the
residues positively associated with it (‘‘adapted’’ associations) and/
or negatively associated with it (‘‘nonadapted’’ associations) are
located at codons 146, 147, 215, 228, 230, 241, 243, 248, 256,
310, 340 and 373. If position 242 is considered the ‘‘target
variable’’, then the covarying residues positively and negatively
associated with it are located at codons 109, 219, 292, 373, 469
and 473. It is important to note in the case of aa-aa associations,
the use of ‘‘predictor’’ and ‘‘target’’ terminology should not be
interpreted as suggesting a directional association between these
polymorphisms or a specific temporal order of selection; rather, it
is more appropriate to simply interpret these as codon-codon
pairs. Therefore, if one is interested using Table S2 to look up all
codons positively and/or negatively associated with Gag codon
242, one should investigate all ‘‘target’’ codons that appear when
242 is set as the ‘‘predictor’’ variable, and vice versa. The union of
these two queries will provide a list of specific codons and residues
that are positively and/or negatively associated with variation at
codon 242.
Note that our analysis also identifies ‘‘two-hop’’ associations
(meaning, codons that positively and/or negatively covary with the
‘‘one-hop’’ sites), however these are not shown on the figure due to
the high density of the resulting networks. The full list of
intraprotein covarying codons is provided in Table S2.
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Figure 1. Gag Immune Escape Map. Escape maps indicate the locations, specific residues and HLA restrictions of HLA-associated polymorphisms.
The HIV-1 consensus B amino acid sequence is used as a reference. Alternating black and brown letters in the consensus amino acid sequence
distinguish the different proteins in HIV-1 Gag (p17, p24, p2, p7, p1, p6). One hundred amino acids are displayed per line. Shaded vertical bars
separate blocks of 10 amino acids. ‘‘Adapted’’ amino acids (those enriched in the presence of the HLA allele) are red. ‘‘Non-adapted’’ amino acids
(those depleted in the presence of the HLA allele) are blue. UPPERCASE letters distinguish polymorphisms that survive correction for HIV codon
covariation (‘‘direct’’ associations), while lowercase letters distinguish polymorphisms that do not survive correction for codon covariation (‘‘indirect’’
associations). Polymorphisms associated with the same HLA allele that occur in proximity to one another are grouped together in yellow boxes.
Optimally-defined CTL epitopes containing HLA-associated polymorphisms are indicated above the consensus sequence. Note that the escape map
does not list the locations of all published CTL epitopes. This is available at http://www.hiv.lanl.gov/content/immunology. The escape maps show all
HLA-associated polymorphisms with q#0.05. A complete listing of all HLA-associated polymorphisms with q#0.2 is provided in Table S1.
doi:10.1371/journal.pone.0006687.g001
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Discussion
HLA-associated polymorphisms were identified in HIV-1 Gag, Pol
and Nef in a combined cohort of .1500 chronically-infected,
treatment-naı¨ve individuals from established cohorts in Canada, the
USA and Western Australia. These cohorts have previously been
independently investigated for HLA-associated polymorphisms; how-
ever by merging the data and re-analyzing as a whole, we achieved the
highest-powered dataset to date to identify HLA associations in HIV
subtype B. Indeed, where previous studies had employed a significance
threshold of q#0.2 when reporting associations, here we have lowered
the threshold to q#0.05, thus focusing on sites with the strongest
statistical support for HLA-driven adaptation.
The current immune escape maps incorporate some improve-
ments over previous iterations. Firstly, the maps cover all proteins
in Pol (including RNAseH and Integrase), instead of just protease/
RT as in previous studies [15]. Secondly, all associations,
regardless of proximity to known epitopes, are displayed on a
single map so that escape patterns in a protein can be visualized
globally. Note that, in the case where an HLA-associated
polymorphism does not fall within a known optimally-described
epitope, we have not attempted to predict the likeliest epitope as
has been done previously. This was done in order to avoid forcing
an epitope prediction in the case where the HLA association may
be attributable to another mechanism (for example a processing
escape mutation occurring distant from a published epitope), and
also to avoid favoring a particular epitope prediction algorithm
among the many that are available (e.g.: MotifScan http://www.
hiv.lanl.gov/content/
immunology/motif_scan; Epipred http://atom.research.micro-
soft.com/bio/epipred.aspx [55]; SYFPEITHI http://www.syf-
peithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm, [56],
NetCTL 1.2 http://www.cbs.dtu.dk/services/NetCTL/ [57],
and various others [58,59]). That being said, visual inspection of
the maps reveals strong evidence for the existence of a number of
novel CTL epitopes, particularly in Pol where epitope mapping
initiatives may not have been as exhaustive compared to Gag and
Nef. Thirdly, the incorporation of a multivariate correction for
HLA linkage disequilibrium allows the identification of the HLA
allele directly responsible for the association, rather than the
manual assignment of the responsible allele using p-values post-
hoc as employed in previous studies [15]. Finally, the incorpora-
tion of a multivariate correction for codon covariation represents
an important step forward [27]. It allows us to discriminate HIV
polymorphisms directly attributable to selection pressure by the
HLA allele in question, from those who may be better explained
indirectly (meaning that their occurrence may be better explained
by the presence of an HLA-associated covarying residue, rather
than possession of the allele itself). In addition, it allows us to
comprehensively identify positively and negatively covarying
amino acids across proteins (Table S2), thus providing candidate
lists for secondary and/or compensatory mutations associated with
known escape sites. Indeed, Carlson et al. [27] demonstrated that
the codon covariation analysis accurately re-capitulates known
pathways of B*57 and B*27-associated escape in Gag [35,36,60],
supporting the use of this tool for the identification of secondary
escape patterns for additional HLA-associated escape mutations.
Just as the standardized identification of drug resistance mutations
[39] has been essential to both basic research as well as the clinical
monitoring of HIV-infected individuals, we hope that the identifica-
tion of immune escape pathways will be equally relevant to HIV
immunology/virology research and AIDS vaccine design. Our results
confirm the strong influence of immune escape on HIV diversity
[13,14], but more importantly underscore the reproducibility and
predictability of immune escape in response to specific HLA pressures
[15,27,28,29,38]. We hope these maps and tables will be useful to
those interested in CTL epitope discovery, the effects of escape and
compensatory mutations on viral replication and pathogenesis, the
design of novel vaccines, as well as the broader question of host-
pathogen co-evolution. Finally, we have assigned the name
‘‘International HIV Adaptation Collaborative’’ (IHAC) to describe
the current multicenter cohort with the hope that this initiative may
be expanded to include additional cohorts worldwide in the future. In
particular, the merging of data and cohorts across different HIV-1
subtypes [27] will allow us to further explore similarities and
differences in HLA-driven polymorphism patterns across subtypes.
Supporting Information
Table S1 HLA-associated polymorphisms in HIV-1 Gag,
Protease, Reverse Transcriptase, Integrase and Nef (all q,0.2).
Consistent with the immune escape maps, amino acid numbering
begins with 1 for each individual protein (where individual
proteins are defined as Gag, Protease, Reverse Transcriptase,
Integrase and Nef). Also consistent with the escape maps, the
direction of the association (adapted vs. nonadapted) for the
specific HLA in question is differentiated by red and blue lettering,
respectively. Direct (covariation-corrected) and indirect (non-
Figure 2. Protease Immune Escape Map.
doi:10.1371/journal.pone.0006687.g002
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Figure 3. Reverse Transcriptase Immune Escape Map.
doi:10.1371/journal.pone.0006687.g003
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covariation corrected) are also differentiated. P- and q-values
represent the minimum values observed in the covariation
corrected and non-covariation corrected analyses.
Found at: doi:10.1371/journal.pone.0006687.s001 (0.23 MB
XLS)
Table S2 Amino acid-amino acid (aa-aa) associations in HIV-1
Gag, Protease, Reverse Transcriptase, Integrase and Nef (all
q,0.2). Consistent with the immune escape maps and supple-
mentary table 1, amino acid numbering begins with 1 for each
individual protein. Predictor Codon and Target Codon refer to
the predictor and target attributes, respectively, however it is
important to note that this terminology does not imply a specific
direction of association. For example, if one is interested in all
codons that covary with Gag codon 242, one should investigate all
target codons that appear when 242 is set as the predictor variable,
and vice versa. The union of these two searches will provide a list
of candidate codons that covary with codon 242. In the case of aa-
aa associations, adapted refers to positive associations (ie amino
acid pairs that statistically tend to co-exist/co-vary) while
nonadapted identifies negative associations (ie amino acids that
statistically tend not to be found together). Finally, note that in the
original analysis, HIV codon covariation was analyzed across all
three Pol proteins simultaneously. However, to maintain consis-
tency with Figures 1-5 in the paper, the data listed in this
supplementary table are limited to intra-protein associations only,
a fact which should be considered when interpreting the q-values
for aa-aa associations in Protease, RT and Integrase.
Found at: doi:10.1371/journal.pone.0006687.s002 (1.13 MB
XLS)
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